

Margarita Sanchez-Beato

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2422567/publications.pdf>

Version: 2024-02-01

104
papers

4,372
citations

81839

39
h-index

114418

63
g-index

104
all docs

104
docs citations

104
times ranked

5585
citing authors

#	ARTICLE	IF	CITATIONS
1	Cell cycle deregulation in B-cell lymphomas. <i>Blood</i> , 2003, 101, 1220-1235.	0.6	329
2	PLCG1 mutations in cutaneous T-cell lymphomas. <i>Blood</i> , 2014, 123, 2034-2043.	0.6	193
3	p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. <i>British Journal of Cancer</i> , 1994, 69, 337-341.	2.9	173
4	Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. <i>Blood</i> , 2008, 112, 3088-3098.	0.6	173
5	Analysis of the IgVH somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. <i>Blood</i> , 2002, 99, 1299-1304.	0.6	158
6	7q31-32 Allelic Loss Is a Frequent Finding in Splenic Marginal Zone Lymphoma. <i>American Journal of Pathology</i> , 1999, 154, 1583-1589.	1.9	154
7	Progression to Large B-Cell Lymphoma in Splenic Marginal Zone Lymphoma. <i>American Journal of Surgical Pathology</i> , 2001, 25, 1268-1276.	2.1	126
8	Cancer induction by restriction of oncogene expression to the stem cell compartment. <i>EMBO Journal</i> , 2009, 28, 8-20.	3.5	125
9	Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. <i>Blood</i> , 2003, 101, 4042-4046.	0.6	121
10	Loss of p16/INK4A Protein Expression in Non-Hodgkin's Lymphomas Is a Frequent Finding Associated with Tumor Progression. <i>American Journal of Pathology</i> , 1998, 153, 887-897.	1.9	111
11	Nodal Marginal Zone Lymphoma: A Heterogeneous Tumor. <i>American Journal of Surgical Pathology</i> , 2003, 27, 762-771.	2.1	106
12	Nodal marginal zone lymphoma: gene expression and miRNA profiling identify diagnostic markers and potential therapeutic targets. <i>Blood</i> , 2012, 119, e9-e21.	0.6	91
13	Variability in the expression of polycomb proteins in different normal and tumoral tissues. A pilot study using tissue microarrays. <i>Modern Pathology</i> , 2006, 19, 684-694.	2.9	83
14	PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma. <i>Blood</i> , 2011, 118, 5517-5527.	0.6	83
15	MicroRNA signatures in B-cell lymphomas. <i>Blood Cancer Journal</i> , 2012, 2, e57-e57.	2.8	79
16	Mantle cell lymphoma: transcriptional regulation by microRNAs. <i>Leukemia</i> , 2010, 24, 1335-1342.	3.3	72
17	Splenic small B-cell lymphoma with predominant red pulp involvement: a diffuse variant of splenic marginal zone lymphoma?. <i>Histopathology</i> , 2002, 40, 22-30.	1.6	70
18	Overall Survival in Aggressive B-Cell Lymphomas Is Dependent on the Accumulation of Alterations in p53, p16, and p27. <i>American Journal of Pathology</i> , 2001, 159, 205-213.	1.9	68

#	ARTICLE	IF	CITATIONS
19	The role of miRNAs in the pathogenesis and diagnosis of B-cell lymphomas. <i>Blood</i> , 2012, 120, 1782-1790.	0.6	68
20	SUZ12 Promotes Human Epithelial Ovarian Cancer by Suppressing Apoptosis via Silencing HRK. <i>Molecular Cancer Research</i> , 2012, 10, 1462-1472.	1.5	66
21	Abnormal PcG protein expression in Hodgkin's lymphoma. Relation with E2F6 and NF- κ B transcription factors. <i>Journal of Pathology</i> , 2004, 204, 528-537.	2.1	63
22	Analysis of Octamer-Binding Transcription Factors Oct2 and Oct1 and their coactivator BOB.1/OBF.1 in Lymphomas. <i>Modern Pathology</i> , 2002, 15, 211-220.	2.9	62
23	Silencing of the p18INK4c gene by promoter hypermethylation in Reed-Sternberg cells in Hodgkin lymphomas. <i>Blood</i> , 2004, 103, 2351-2357.	0.6	60
24	Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma. <i>Haematologica</i> , 2015, 100, e450-e453.	1.7	59
25	Oxidative Phosphorylation Induces De Novo Expression of the MHC Class I in Tumor Cells through the ERK5 Pathway. <i>Journal of Immunology</i> , 2010, 185, 3498-3503.	0.4	58
26	Polycomb proteins in hematologic malignancies. <i>Blood</i> , 2010, 116, 5465-5475.	0.6	56
27	p21WAF1/CIP1 AND MDM2 EXPRESSION IN NON-HODGKIN'S LYMPHOMA AND THEIR RELATIONSHIP TO p53 STATUS: A p53+, MDM2 ⁺ , p21 ⁺ IMMUNOPHENOTYPE ASSOCIATED WITH MISSENSE p53 MUTATIONS. , 1997, 181, 51-61.		55
28	p14ARF nuclear overexpression in aggressive B-cell lymphomas is a sensor of malfunction of the common tumor suppressor pathways. <i>Blood</i> , 2002, 99, 1411-1418.	0.6	53
29	The RHOA G17V gene mutation occurs frequently in peripheral T-cell lymphoma and is associated with a characteristic molecular signature. <i>Blood</i> , 2014, 123, 2893-2894.	0.6	53
30	NIK Controls Classical and Alternative NF- κ B Activation and Is Necessary for the Survival of Human T-cell Lymphoma Cells. <i>Clinical Cancer Research</i> , 2013, 19, 2319-2330.	3.2	52
31	B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies. <i>Haematologica</i> , 2014, 99, 222-231.	1.7	52
32	Retinoblastoma (rb) gene product expression in lymphomas. Correlation with Ki67 growth fraction. <i>Journal of Pathology</i> , 1993, 169, 405-412.	2.1	51
33	Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naïve patients. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 814-823.	1.9	50
34	Epstein-Barr virus microRNAs repress BCL6 expression in diffuse large B-cell lymphoma. <i>Leukemia</i> , 2012, 26, 180-183.	3.3	50
35	A Short Mutational Hot Spot in the First Intron of BCL-6 Is Associated with Increased BCL-6 Expression and with Longer Overall Survival in Large B-Cell Lymphomas. <i>American Journal of Pathology</i> , 2002, 160, 1371-1380.	1.9	47
36	TCL1A expression delineates biological and clinical variability in B-cell lymphoma. <i>Modern Pathology</i> , 2009, 22, 206-215.	2.9	46

#	ARTICLE	IF	CITATIONS
37	Splenic marginal zone lymphoma: comprehensive analysis of gene expression and miRNA profiling. <i>Modern Pathology</i> , 2013, 26, 889-901.	2.9	45
38	Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas. <i>Cancer Treatment Reviews</i> , 2015, 41, 680-689.	3.4	43
39	Deregulated Expression of the Polycomb-Group Protein SUZ12 Target Genes Characterizes Mantle Cell Lymphoma. <i>American Journal of Pathology</i> , 2010, 177, 930-942.	1.9	41
40	p27KIP1 is abnormally expressed in Diffuse Large B-Cell Lymphomas and is associated with an adverse clinical outcome. <i>British Journal of Cancer</i> , 1999, 80, 1427-1434.	2.9	40
41	Epstein-Barr Virus-Latent Membrane Protein 1 Expression Has a Favorable Influence in the Outcome of Patients with Hodgkin's Disease Treated with Chemotherapy. <i>Leukemia and Lymphoma</i> , 2000, 39, 563-572.	0.6	39
42	Extreme sensitivity to Yondelis® (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. <i>Journal of Cellular Biochemistry</i> , 2007, 100, 339-348.	1.2	39
43	New Mutations in Chronic Lymphocytic Leukemia Identified by Target Enrichment and Deep Sequencing. <i>PLoS ONE</i> , 2012, 7, e38158.	1.1	38
44	Recurrent presence of the PLCG1 S345F mutation in nodal peripheral T-cell lymphomas. <i>Haematologica</i> , 2015, 100, e25-e27.	1.7	37
45	Mouse cDNA microarray analysis uncovers Slug targets in mouse embryonic fibroblasts. <i>Genomics</i> , 2006, 87, 113-118.	1.3	34
46	Proliferation centers in chronic lymphocytic leukemia: the niche where NF- κ B activation takes place. <i>Leukemia</i> , 2010, 24, 872-876.	3.3	34
47	Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas. <i>Haematologica</i> , 2013, 98, 57-64.	1.7	33
48	Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets. <i>Oncotarget</i> , 2017, 8, 111386-111395.	0.8	33
49	Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma. <i>PLoS ONE</i> , 2019, 14, e0212813.	1.1	31
50	Overlap at the molecular and immunohistochemical levels between angioimmunoblastic T-cell lymphoma and a subgroup of peripheral T-cell lymphomas without specific morphological features. <i>Oncotarget</i> , 2018, 9, 16124-16133.	0.8	30
51	Molecular heterogeneity of splenic marginal zone lymphomas: analysis of mutations in the 5' non-coding region of the bcl-6 gene. <i>Leukemia</i> , 2001, 15, 628-634.	3.3	29
52	Unique Phenotypic Profile of Monocytoid B Cells. <i>American Journal of Pathology</i> , 2001, 158, 1363-1369.	1.9	27
53	NF- κ B expression is a feature of both activated B-cell-like and germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. <i>Modern Pathology</i> , 2014, 27, 1331-1337.	2.9	27
54	Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial. <i>Leukemia</i> , 2021, 9, e002323.		26

#	ARTICLE	IF	CITATIONS
55	Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma. <i>Scientific Reports</i> , 2021, 11, 1886.	1.6	25
56	Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers. <i>Blood Advances</i> , 2021, 5, 5588-5598.	2.5	24
57	MDM2 AND p21WAF1/CIP1, WILD-TYPE p53-INDUCED PROTEINS, ARE REGULARLY EXPRESSED BY STERNBERG-REED CELLS IN HODGKIN'S DISEASE. , 1996, 180, 58-64.		23
58	Analysis of the frequency of microsatellite instability and p53 gene mutation in splenic marginal zone and MALT lymphomas. <i>Journal of Clinical Pathology</i> , 1998, 51, 262-267.	2.1	23
59	Genomic analyses of microdissected Hodgkin and Reed-Sternberg cells: mutations in epigenetic regulators and p53 are frequent in refractory classic Hodgkin lymphoma. <i>Blood Cancer Journal</i> , 2019, 9, 34.	2.8	23
60	Mutational profile of primary breast diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 102888-102897.	0.8	22
61	Hodgkin's lymphoma cells express alternatively spliced forms of HDM2 with multiple effects on cell cycle control. <i>Oncogene</i> , 2006, 25, 2565-2574.	2.6	21
62	Chronic lymphocytic leukemia cells in lymph nodes show frequent NOTCH1 activation. <i>Haematologica</i> , 2015, 100, e200-e203.	1.7	21
63	Transcriptomal profiling of the cellular response to DNA damage mediated by Slug (Snai2). <i>British Journal of Cancer</i> , 2008, 98, 480-488.	2.9	18
64	PIM Kinases as Potential Therapeutic Targets in a Subset of Peripheral T Cell Lymphoma Cases. <i>PLoS ONE</i> , 2014, 9, e112148.	1.1	18
65	Expression of p21WAF1/CIP1 in fetal and adult tissues: simultaneous analysis with Ki67 and p53.. <i>Journal of Clinical Pathology</i> , 1997, 50, 645-653.	1.0	17
66	Development of a Real-Time Reverse Transcription Polymerase Chain Reaction Assay for c-myc Expression That Allows the Identification of a Subset of c-myc+ Diffuse Large B-Cell Lymphoma. <i>Laboratory Investigation</i> , 2003, 83, 143-152.	1.7	17
67	Mutations in the <sc>JAK</sc>/<sc>STAT</sc> pathway genes and activation of the pathway, a relevant finding in nodal Peripheral Tâ€cell lymphoma. <i>British Journal of Haematology</i> , 2018, 183, 497-501.	1.2	17
68	Nucleolar p14ARF Overexpression in Reed-Sternberg Cells in Hodgkin's Lymphoma. <i>American Journal of Pathology</i> , 2002, 160, 569-578.	1.9	16
69	Anomalous retinoblastoma protein expression in Sternberg-Reed cells in Hodgkin's disease: a comparative study with p53 and Ki67 expression. <i>British Journal of Cancer</i> , 1996, 74, 1056-1062.	2.9	15
70	An A91V SNP in the Perforin Gene Is Frequently Found in NK/T-Cell Lymphomas. <i>PLoS ONE</i> , 2014, 9, e91521.	1.1	13
71	Concordance between circulating tumor cells and clinical status during follow-up in anaplastic lymphoma kinase (ALK) non-small-cell lung cancer patients. <i>Oncotarget</i> , 2017, 8, 59408-59416.	0.8	12
72	Somatic hypermutation signature in B-cell low-grade lymphomas. <i>Haematologica</i> , 2008, 93, 1186-1194.	1.7	11

#	ARTICLE	IF	CITATIONS
73	Functional signatures identified in B-cell non-Hodgkin lymphoma profiles. <i>Leukemia and Lymphoma</i> , 2009, 50, 1699-1708.	0.6	10
74	HDAC inhibitors induce cell cycle arrest, activate the apoptotic extrinsic pathway and synergize with a novel PIM inhibitor in Hodgkin lymphoma-derived cell lines. <i>British Journal of Haematology</i> , 2011, 152, 352-356.	1.2	10
75	New drugs and targeted treatments in Hodgkin's lymphoma. <i>Cancer Treatment Reviews</i> , 2014, 40, 457-464.	3.4	10
76	Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group. <i>Hematological Oncology</i> , 2019, 37, 143-150.	0.8	9
77	Biallelic ATM alterations detected at diagnosis identify a subset of treatment-naïve chronic lymphocytic leukemia patients with reduced overall survival similar to patients with p53 deletion. <i>Leukemia and Lymphoma</i> , 2017, 58, 859-865.	0.6	8
78	Clonal dynamics monitoring during clinical evolution in chronic lymphocytic leukaemia. <i>Scientific Reports</i> , 2019, 9, 975.	1.6	8
79	An Overview on Diffuse Large B-Cell Lymphoma Models: Towards a Functional Genomics Approach. <i>Cancers</i> , 2021, 13, 2893.	1.7	6
80	Does the presence of hepatitis virus B and C influence the evolution of diffuse large B-cell lymphoma?. <i>Leukemia and Lymphoma</i> , 2015, 56, 1686-1690.	0.6	5
81	Activity and safety of topical pimecrolimus in patients with early stage mycosis fungoides (PimTo-MF): a single-arm, multicentre, phase 2 trial. <i>Lancet Haematology</i> , 2022, 9, e425-e433.	2.2	5
82	Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis. <i>Clinical Cancer Research</i> , 2022, 28, 3658-3668.	3.2	5
83	Molecular basis of targeted therapy in T/NK-cell lymphoma/leukemia: A comprehensive genomic and immunohistochemical analysis of a panel of 33 cell lines. <i>PLoS ONE</i> , 2017, 12, e0177524.	1.1	4
84	PD-1 loss and T-cell exhaustion in CTCL tumoral T cells. <i>Blood</i> , 2021, 138, 1201-1203.	0.6	4
85	Two distinct molecular subtypes of chronic lymphocytic leukemia give new insights on the pathogenesis of the disease and identify novel therapeutic targets. <i>Leukemia and Lymphoma</i> , 2016, 57, 134-142.	0.6	3
86	MDM2 AND p21WAF1CIP1, WILD-TYPE p53-INDUCED PROTEINS, ARE REGULARLY EXPRESSED BY STERNBERG-REED CELLS IN HODGKIN'S DISEASE. <i>Journal of Pathology</i> , 1996, 180, 58-64.	2.1	2
87	Branched clonal evolution: nodal follicular lymphoma and primary diffuse large B-cell lymphoma of the central nervous system. <i>Haematologica</i> , 2019, 104, e326-e329.	1.7	1
88	Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM). <i>PLoS ONE</i> , 2021, 16, e0257353.	1.1	1
89	Characterization of Subclonal Changes Along Progression in Multiple Myeloma. <i>Blood</i> , 2012, 120, 2924-2924.	0.6	1
90	Abstract 51: Activating PLCG1 mutations in cutaneous T-cell lymphomas. , 2013, , .		1

#	ARTICLE	IF	CITATIONS
91	An integrated prognostic model for diffuse large B-cell lymphoma treated with immunochemotherapy. <i>EJHaem</i> , 2022, 3, 722-733.	0.4	1
92	Sequential Gene Expression Analysis During the Early Alloreactive Phenomena After Allogeneic BMT Identifies Gene Sets and Pathways Differentially Expressed in the Skin and the Blood of BMT Recipients: Implications for the Discovery of Biomarkers of Cutaneous GVHD That Are Relevant to the Target Organ. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, S324.	2.0	0
93	NIK and the Alternative NF- κ B Pathway in Human Lymphomas. <i>Blood</i> , 2009, 114, 3943-3943.	0.6	0
94	PI3KCA and PIM Inhibitors in Peripheral T-Cell Lymphomas. <i>Blood</i> , 2010, 116, 4917-4917.	0.6	0
95	Pharmacological Inhibition of PIM Kinases In Chronic Lymphocytic Leukemia Cases with Unfavorable Prognosis Markers. <i>Blood</i> , 2010, 116, 2468-2468.	0.6	0
96	Targeting the Apoptotic Pathway by TW-37, a Novel Bcl-2 Family Small Molecule Inhibitor, In CLL Primary Samples. <i>Blood</i> , 2010, 116, 2470-2470.	0.6	0
97	MicroRNA Signatures In B-Cell Lymphomas. <i>Blood</i> , 2010, 116, 4155-4155.	0.6	0
98	PIM Kinases Inhibition, a Rational Strategy in Peripheral T-Cell Lymphomas. <i>Blood</i> , 2011, 118, 3494-3494.	0.6	0
99	PI3K Inhibition As a Potential Therapeutic Strategy in Peripheral T-Cell Lymphomas. <i>Blood</i> , 2011, 118, 3493-3493.	0.6	0
100	Mutational Status of Splenic Marginal Zone Lymphoma Revealed by Whole Exome Sequencing. <i>Blood</i> , 2012, 120, 2698-2698.	0.6	0
101	Mutations in PLCG1 Is a Frequent Event in Cutaneous T-Cell Lymphomas. <i>Blood</i> , 2012, 120, 300-300.	0.6	0
102	Tumour Suppressor Genes in Hodgkin's Disease. , 1995, , 209-222.		0
103	A Role of JAK/STAT Pathway in Cutaneous T-Cell Lymphomas: Exploring Its Effects for Targeted Therapy. <i>Blood</i> , 2014, 124, 4498-4498.	0.6	0
104	Diffuse Large B Cell Lymphoma Genetic Classification By Targeted Sequencing and Associations with Immunochemotherapy-Treated Patients' Clinical Outcome. <i>Blood</i> , 2020, 136, 24-25.	0.6	0